S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
LON:DEST

Destiny Pharma (DEST) Share Forecast, Price & News

GBX 45.50
0.00 (0.00%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
45.50
46.20
50-Day Range
41
52
52-Week Range
40
162.20
Volume
70 shs
Average Volume
40,404 shs
Market Capitalization
£33.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive DEST News and Ratings via Email

Sign-up to receive the latest news and ratings for Destiny Pharma and its competitors with MarketBeat's FREE daily newsletter.

Destiny Pharma logo

About Destiny Pharma

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal that is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal, which is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm for the treatment of of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF Drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreement with China Medical System Holdings Limited; research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis; research collaboration with the University of Sheffield; research collaboration with Aston University to investigate novel compounds from its XF-drug platform; collaboration with Cardiff University and Tianjin Medical University; and Collaboration with SporeGen Limited to co-develop treatment for COVID-19. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Sales & Book Value

Annual Sales
£135.03 thousand
Cash Flow
GBX 7.55 per share
Book Value
GBX 12.50 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£33.35 million
Optionable
Optionable

Company Calendar

Last Earnings
9/17/2020
Today
5/22/2022

MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Destiny Pharma (LON:DEST) Frequently Asked Questions

How were Destiny Pharma's earnings last quarter?

Destiny Pharma plc (LON:DEST) released its quarterly earnings results on Thursday, September, 17th. The company reported ($5.50) earnings per share for the quarter.
View Destiny Pharma's earnings history
.

Who are Destiny Pharma's key executives?
Destiny Pharma's management team includes the following people:
  • Mr. Neil Robert Clark, CEO & Director (Age 59, Pay $325k)
  • Dr. William Guy Love, Founder, Chief Scientific Officer & Director (Age 59, Pay $275k)
  • Mr. Shaun Claydon ACA, CFO, Company Sec. & Director (Age 53, Pay $240k)
  • Dr. Jesús M González Moreno, Chief Medical Officer
  • Dr. Stephanie Bewick, Chief Bus. Officer
What other stocks do shareholders of Destiny Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include Dynavax Technologies (DVAX), AFPO.L (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB) and EQTEC (EQT).

What is Destiny Pharma's stock symbol?

Destiny Pharma trades on the London Stock Exchange (LON) under the ticker symbol "DEST."

How do I buy shares of Destiny Pharma?

Shares of DEST and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Destiny Pharma's stock price today?

One share of DEST stock can currently be purchased for approximately GBX 45.50.

How much money does Destiny Pharma make?

Destiny Pharma has a market capitalization of £33.35 million and generates £135.03 thousand in revenue each year.

How many employees does Destiny Pharma have?

Destiny Pharma employs 14 workers across the globe.

What is Destiny Pharma's official website?

The official website for Destiny Pharma is www.destinypharma.com.

How can I contact Destiny Pharma?

Destiny Pharma's mailing address is Sussex Innovation Centre Science Park Square, Falmer, BRIGHTON, BN1 9SB, United Kingdom. The company can be reached via phone at +44-1273-704440.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.